Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BYScientific Reports

Development of a pH-sensitive magnetic hydrogel based on chitosan for synergistic chemo/hyperthermia treatment of MCF-7 breast cancer cells

  • Fatemeh Ghobadi1
  • Faranak Aghaz2
  • Soheila Zare3
  • Mehdi Jaymand2
  • Hossein Derakhshankhah4
4 affiliations
  1. 1Students Research Committee, Kermanshah University of Medical Sciences
  2. 2Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences
  3. 3Medicinal Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences
  4. 4Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences
Read full textPDFDOICite

Abstract

A pH-responsive magnetic hydrogel was created based on chitosan (CS) for synergistic chemo/hyperthermia therapy of MCF-7 breast cancer cells. For this goal, a mixture of carboxymethylated chitosan (CS-COOH), vinyl acetate monomer (VAc), and methacrylate end-capped magnetic nanoparticles (Fe3O4 NPs) was copolymerized in the presence of a crosslinker to produce a CS-cl-PVAc/Fe3O4 nanocomposite. Drug delivery system (DDS) was obtained after hydrolysis of acetate groups in PVAc segments to hydroxyl groups, in order to covert PVAc to poly(vinyl alcohol) (PVA). The developed DDS showed acceptable saturation magnetization value (8.82 emug− 1), swelling ratio (2730 ± 78%), degradation rate (59 ± 7.5 wt%), protein adsorption capacity (0.192 ± 0.03µgmg), and low hemolysis rate (4.78 ± 0.08%). Doxorubicin (Dox) loading (LE) and entrapment efficiencies for the developed CS-cl-PVA/Fe3O4 nanocomposite hydrogel were quantified as 2.13 and 64.5%, respectively. The DDS showed pH-responsiveness drug release behavior. It was established that the formulated drug has higher release value (80.1%) at cancerous condition (pH 5.5) than the physiological condition (38.7%). The cytocompatibility of the created DDS was approved via MTT-assay on HSF-PI-16 fibroblast cells. Synergistic chemo/hyperthermia therapy with Dox-loaded system showed higher anticancer performance (IC50 = ~ 25 µgmL− 1) than those of the chemotherapy alone (IC50 = ~ 32 µgmL− 1).

Related

  1. Origin of Fe ions in ROS production induced in magnetic hyperthermia anti-cancer nanotherapy: release from iron oxide nanoparticles or not?
    Justine Journaux-Duclos, Megi Bejko, Pascal Clerc +8
    HALPreprintCC BY-SA 4.0Full textSystems & synthetic biologyOncologyHAL
  2. Development and validation of a magnetic resonance imaging-based model for the prediction of progression-free survival before initial treatment of hypopharyngeal cancer treated with chemoradiation
    Hengmin Tao, Jia Wei, Qiqi Zheng +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textMedical imaging & radiologyCrossref
  3. Development and internal validation of a pretreatment magnetic resonance imaging-based radiomics prediction model for 1-year overall survival in treatment-naïve patients with hepatocellular carcinoma receiving transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors.
    Chengyi Jiang, Shuai Zhang, Beiguang Zhang +6
    Journal of gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  4. Targeted dual-responsive nanocapsules for synergistic cisplatin and paclitaxel prodrug delivery in the treatment of lung cancer
    Xinyu Wang, Dan Qin, Chunyu Yao +10
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Synergistic nanotheranostic platform for fluorescence/magnetic resonance bimodal imaging-guided near infrared photoimmuno-chemodynamic thermal targeting therapy.
    Kohei Matsuoka, Mizuki Yamada, Ryu Okada +12
    Journal of nanobiotechnologyPeer-reviewedCC BY-NC-NDFull textSystems & synthetic biologyGeneral medicineEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{ghobadi2026development,
  title = {{Development of a pH-sensitive magnetic hydrogel based on chitosan for synergistic chemo/hyperthermia treatment of MCF-7 breast cancer cells}},
  author = {Fatemeh Ghobadi and Faranak Aghaz and Soheila Zare and Mehdi Jaymand and Hossein Derakhshankhah},
  journal = {Scientific Reports},
  year = {2026},
  month = jul,
  doi = {10.1038/s41598-026-62690-1},
  url = {https://doi.org/10.1038/s41598-026-62690-1},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Development of a pH-sensitive magnetic hydrogel based on chitosan for synergistic chemo/hyperthermia treatment of MCF-7 breast cancer cells
AU  - Fatemeh Ghobadi
AU  - Faranak Aghaz
AU  - Soheila Zare
AU  - Mehdi Jaymand
AU  - Hossein Derakhshankhah
PY  - 2026
DA  - 2026/07/01
JO  - Scientific Reports
DO  - 10.1038/s41598-026-62690-1
UR  - https://doi.org/10.1038/s41598-026-62690-1
AB  - A pH-responsive magnetic hydrogel was created based on chitosan (CS) for synergistic chemo/hyperthermia therapy of MCF-7 breast cancer cells. For this goal, a mixture of carboxymethylated chitosan (CS-COOH), vinyl acetate monomer (VAc), and methacrylate end-capped magnetic nanoparticles (Fe3O4 NPs) was copolymerized in the presence of a crosslinker to produce a CS-cl-PVAc/Fe3O4 nanocomposite. Drug delivery system (DDS) was obtained after hydrolysis of acetate groups in PVAc segments to hydroxyl groups, in order to covert PVAc to poly(vinyl alcohol) (PVA). The developed DDS showed acceptable saturation magnetization value (8.82 emug− 1), swelling ratio (2730 ± 78%), degradation rate (59 ± 7.5 wt%), protein adsorption capacity (0.192 ± 0.03µgmg), and low hemolysis rate (4.78 ± 0.08%). Doxorubicin (Dox) loading (LE) and entrapment efficiencies for the developed CS-cl-PVA/Fe3O4 nanocomposite hydrogel were quantified as 2.13 and 64.5%, respectively. The DDS showed pH-responsiveness drug release behavior. It was established that the formulated drug has higher release value (80.1%) at cancerous condition (pH 5.5) than the physiological condition (38.7%). The cytocompatibility of the created DDS was approved via MTT-assay on HSF-PI-16 fibroblast cells. Synergistic chemo/hyperthermia therapy with Dox-loaded system showed higher anticancer performance (IC50 = ~ 25 µgmL− 1) than those of the chemotherapy alone (IC50 = ~ 32 µgmL− 1).
SN  - 2045-2322
ER  -